2025
Biomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease
Li M, Jiang L, Liu Z, You R, Li Y, Xiang C, Yang L, Zhang H, Zhou X. Biomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease. Integrative Medicine In Nephrology And Andrology 2025, 12 DOI: 10.1097/imna-d-24-00050.Peer-Reviewed Original ResearchAutosomal dominant tubulointerstitial kidney diseaseChronic kidney diseaseTubulointerstitial kidney diseaseKidney diseaseProgressive chronic kidney diseaseDelay kidney failureVariable clinical featuresUric acid levelsControl blood pressureRenal interstitial fibrosisImprove patient outcomesPotential therapeutic targetClinical featuresClinical manifestationsTreatment optionsInterstitial fibrosisInsidious onsetClinical indicationsDisease progressionTubular proteinuriaEarly diagnosisBlood pressurePathological featuresAdvanced stageKidney failureAcceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study
Chayama K, Ng C, Brohman I, Mansoor M, Small W, Philbin M, Collins A, McNeil R. Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study. PLOS ONE 2025, 20: e0319010. PMID: 40019916, PMCID: PMC11870339, DOI: 10.1371/journal.pone.0319010.Peer-Reviewed Original ResearchConceptsAdherence to antiretroviral therapyLong-acting antiretroviral therapyLA-ARTAntiretroviral therapySuboptimal adherence to antiretroviral therapyAdherence barriersProspective cohort studySuboptimal ART adherenceAdverse side effectsPill burdenTreatment optionsSubstance useCohort studyART adherenceTreatment advancesSide effectsTreatment changesPLHIVTreatment approachesTherapyCredible sources of informationPopulation-level benefitsDrugHIVSocial-structural inequitiesCD103+ dendritic cell — fibroblast crosstalk via TLR9, TDO2, and AHR signaling drives lung fibrogenesis
Carter H, Costa R, Adams T, Gilchrist T, Emch C, Bame M, Oldham J, Huang S, Linderholm A, Noth I, Kaminski N, Moore B, Gurczynski S. CD103+ dendritic cell — fibroblast crosstalk via TLR9, TDO2, and AHR signaling drives lung fibrogenesis. JCI Insight 2025, 10 PMID: 39964756, PMCID: PMC11949071, DOI: 10.1172/jci.insight.177072.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDBasic Helix-Loop-Helix Transcription FactorsBleomycinDendritic CellsDisease Models, AnimalFibroblastsHumansIdiopathic Pulmonary FibrosisIntegrin alpha ChainsInterleukin-6LungMaleMiceMice, Inbred C57BLReceptors, Aryl HydrocarbonSignal TransductionToll-Like Receptor 9Tryptophan OxygenaseConceptsIdiopathic pulmonary fibrosisAhR signalingMice treated with BLMIL-17+ cellsCD103+ DCLoss of lung functionStudies of human samplesLimited treatment optionsTreated ex vivoProduction of IL-6Inflammatory cytokine productionExon 2 deletionExpression of TDO2IL-6 productionAdoptive transferCD11c-CreCD11c+ cellsImmunological changesPulmonary fibrosisTLR agonistsProgressive scarringTreatment optionsCytokine productionLung fibrogenesisAryl hydrocarbon receptorSex-based Influences on White Matter Tract Integrity in Alcohol Use Disorder: a Systematic Review
Barrios N, Nartey N, Yue J, Riordan W, Kohler R, Verplaetse T, Roberts W, Carretta R, Banini B, Zhou H, Garcia-Rivas V, Blackford J, Zakiniaeiz Y. Sex-based Influences on White Matter Tract Integrity in Alcohol Use Disorder: a Systematic Review. Current Addiction Reports 2025, 12: 10. PMID: 40343159, PMCID: PMC12058214, DOI: 10.1007/s40429-025-00624-z.Peer-Reviewed Original ResearchWhite matter tract integrityAlcohol use disorderTract integritySex differencesUse disorderNeurotoxic effects of alcoholAlcohol-related health consequencesExamined sex differencesEffects of alcoholAlcohol use historyWell-characterized sampleDiffusion magnetic resonance imagingEvidence of sex-related differencesNeurobiological mechanismsPsychiatric comorbiditiesSubstance useSystematic reviewSex-related differencesNeurotoxic effectsIndividualized treatment optionsMagnetic resonance imagingDisordersAlcoholGoogle Scholar databasesTreatment optionsShort- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature
Taki Y, Kono T, Matsuda T, Kozu R, Fujimoto M, Sakuma I, Hashimoto N, Horiguchi K, Higuchi Y, Tanaka T. Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature. Endocrine Journal 2025, ej24-0548. PMID: 39842795, DOI: 10.1507/endocrj.ej24-0548.Peer-Reviewed Original ResearchSomatostatin receptor 5GLP-1RAsContinuous glucose monitoringGrowth hormoneOptimal first-line treatmentGLP-1 receptor agonistsEfficacy of GLP-1RAsMultireceptor somatostatin analogsEffects of pasireotideFirst-line therapyFirst-line treatmentInsulin-like growth factor-1Optimal treatment strategyControlling hormone levelsEarly detectionGrowth factor-1Pasireotide therapyInhibit insulin secretionSomatostatin analogsFirst-lineReceptor agonistsTreatment optionsPasireotideReceptor 5Treatment strategiesComprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas
Antony V, Sun T, Dolezal D, Cai G. Comprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas. Cancers 2025, 17: 335. PMID: 39941707, PMCID: PMC11815932, DOI: 10.3390/cancers17030335.Peer-Reviewed Original ResearchMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaPrimary pancreatic ductal adenocarcinomaMolecular profilingGene mutationsGene copy number alterationsAdvanced-stage pancreatic cancerInsufficient tumor cellsOncomine Comprehensive AssayRate of TP53Copy number alterationsMetastatic diseasePDAC casesPIK3CA mutationsPancreatic cancerPoor prognosisTreatment optionsDuctal adenocarcinomaTumor cellsTumor progressionMolecular alterationsStudy cohortMolecular testingComprehensive assayTherapeutic targetNav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids
Ghovanloo M, Tyagi S, Zhao P, Waxman S. Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2416886122. PMID: 39835903, PMCID: PMC11789019, DOI: 10.1073/pnas.2416886122.Peer-Reviewed Original ResearchConceptsExcitation of peripheral sensory neuronsTherapeutic potential of cannabinoidsPotential of cannabinoidsPeripheral sensory neuronsVoltage-gated sodiumSpectrum of adverse effectsNociceptor excitabilityPain signalsIn vivo studiesAnalgesic targetsPain treatmentAttenuate painRepetitive firingNav1.8Sensory neuronsTreatment optionsClinical studiesInhibit excitabilityAnalgesic compoundsPainTherapeutic potentialCannabigerolProof-of-principalAdverse effectsTreatmentPhenotype Spectrum of TRPM3‐Associated Disorders
Jolitz L, Helbig I, Fitzgerald M, Ruggiero S, Cohen S, Angelini C, Vallespin E, Michaud V, Gerasimenko A, Cogne B, Isidor B, Keren B, Dyment D, Heron D, Karstensen H, Cuppen I, Christodoulou J, Wilson M, Lake N, Biskup S, Syrbe S, Mori T, Becker L, Kaindl A. Phenotype Spectrum of TRPM3‐Associated Disorders. Annals Of Neurology 2025, 97: 561-570. PMID: 39749750, PMCID: PMC11831877, DOI: 10.1002/ana.27141.Peer-Reviewed Original ResearchConceptsEffective anti-seizure medicationDevelopmental delayGain-of-function variantsDevelopmental delay/intellectual disabilitySpike wave activityAnti-seizure medicationsPreponderance of girlsSystematic literature searchOcular involvementMedian ageMusculoskeletal anomaliesClinical spectrumAxial hypotoniaDysmorphic featuresElectroencephalogram abnormalitiesEffects of treatmentClinical manifestationsTreated patientsEpileptic encephalopathyMonoallelic variantsTreatment optionsFrequent findingPhenotypic spectrumVariant p.Epilepsy phenotypeChapter 52 Obsessive–compulsive disorder
Abdallah S, Olfson E, Fernandez T. Chapter 52 Obsessive–compulsive disorder. 2025, 937-950. DOI: 10.1016/b978-0-443-19176-3.00011-x.ChaptersObsessive-compulsive disorderObsessive-compulsive disorder etiologiesCognitive behavioral therapySerotonin reuptake inhibitorsReuptake inhibitorsBehavioral therapyMedication augmentationNeuroanatomical alterationsNeurochemical imbalanceMedication trialsGenetic influencesImprove treatment outcomesEvidence-based therapeutic strategiesTreatment outcomesRobust clinical trialsDisordersClinical manifestationsTreatment optionsClinical trialsTherapeutic strategiesSerotoninMultifactorial naturePharmacotherapyNeuromodulationTrialsDermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCNNon-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis
Balter D, Cao Y, Garritano J, Micevic G, Sanchez A. Non-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis. Clinical Nephrology - Case Studies 2025, 13: 8-12. PMID: 39949516, PMCID: PMC11823000, DOI: 10.5414/cncs111578.Peer-Reviewed Original ResearchNon-uremic calciphylaxisDermatological complicationsAlcohol-associated cirrhosisPainful skin lesionsAcute kidney injurySodium thiosulfate therapyInfectious complicationsKidney injuryTreatment optionsSkin biopsiesHepatic encephalopathyWork-upSkin lesionsCalciphylaxisCirrhosisComplicationsThiosulfate therapyAlcohol associationsPatientsTreatmentBiopsyPrognosisTherapyLesionsEncephalopathy
2024
Acute Decompensated Valvular Disease in the Intensive Care Unit
Miller P, Senman B, Gage A, Carnicelli A, Jacobs M, Rali A, Senussi M, Bhatt A, Hollenberg S, Kini A, Menon V, Grubb K, Morrow D, Section A. Acute Decompensated Valvular Disease in the Intensive Care Unit. JACC Advances 2024, 3: 101402. PMID: 39735779, PMCID: PMC11681797, DOI: 10.1016/j.jacadv.2024.101402.Peer-Reviewed Original ResearchIntensive care unitCardiac intensive care unitValvular diseaseCritically ill patientsCare unitIll patientsPrimary cardiac disorderMultidisciplinary heart teamModern cardiac intensive care unitPercutaneous interventional therapyDefinitive treatmentSurgical riskClinical presentationSocietal guidelinesHeart teamValvular disordersTreatment optionsInterventional therapyCardiac disordersDiseasePatientsTreatmentDisordersSurgeryTherapyReal-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia.
Huntington S, Rhodes J, Manzoor B, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Marx S, Doshi J. Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia. JCO Oncology Practice 2024, op2400220. PMID: 39705617, DOI: 10.1200/op.24.00220.Peer-Reviewed Original ResearchChronic lymphocytic leukemia treatmentChronic lymphocytic leukemiaFollow-up periodFrontline settingLymphocytic leukemiaTreatment patternsFollow-upReal-world treatment patternsMedian time to discontinuationBruton tyrosine kinase inhibitorAnti-CD20 monotherapyPatients discontinued treatmentMonths of treatmentTime to discontinuationTyrosine kinase inhibitorsReal-world studyPatient-monthsBTKiTreatment optionsVenetoclaxKinase inhibitorsPatientsAll-causeBcl-2MonthsEfficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer.
Ravani L, Calomeni P, Vilbert M, Madeira T, Wang M, Deng D, Testa L, Colombo Bonadio R, Clifton K, Wander S, Lustberg M. Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer. JCO Oncology Practice 2024, op2400649. PMID: 39689274, DOI: 10.1200/op-24-00649.Peer-Reviewed Original ResearchProgression-free survivalAdvanced breast cancerEndocrine therapyOverall survivalDisease progressionET monotherapyHormone receptor-positive/human epidermal growth factor receptor 2-negativeBreast cancerHormone receptor-positive advanced breast cancerAssociated with longer progression-free survivalPooled analysisHR+ HER2- advanced breast cancerCyclin-dependent kinase 4/6 inhibitorsHER2- advanced breast cancerMeta-analysis searching PubMedLonger progression-free survivalProgression-free survival benefitStandard of careIndividual patient dataPatient dataCDK4/6i therapyProlonged OSCDK4/6 inhibitorsCDK4/6iTreatment optionsTreatment Effect Heterogeneity in Acute Kidney Injury Incidence Following Intravenous Antihypertensive Administration for Severe Blood Pressure Elevation During Hospitalization
Ghazi L, Chen X, Harhay M, Hu L, Biswas A, Peixoto A, Li F, Wilson F. Treatment Effect Heterogeneity in Acute Kidney Injury Incidence Following Intravenous Antihypertensive Administration for Severe Blood Pressure Elevation During Hospitalization. American Journal Of Kidney Diseases 2024, 85: 442-453. PMID: 39580068, DOI: 10.1053/j.ajkd.2024.09.011.Peer-Reviewed Original ResearchAcute kidney injuryAcute kidney injury incidenceSevere hypertensionIV antihypertensivesAntihypertensive treatmentBlood pressureRisk of acute kidney injuryAbstractText Label="SETTINGS &Blood pressure elevationSevere blood pressure elevationSystolic blood pressureIdentifying treatment optionsAntihypertensive administrationKidney injuryAbstractText Label="RATIONALETreatment optionsAntihypertensive effectBP elevationPressure elevationPatient characteristicsDiastolic BPPatientsKidney failureAntihypertensivesHospital admissionImpact of Surgeon Volume on Perioperative Complications and Survival to Total Hip Arthroplasty Following Femoral Head Core Decompression
Sanchez J, Jiang W, Dhodapkar M, Radford Z, Seddio A, Li M, Wiznia D, Grauer J. Impact of Surgeon Volume on Perioperative Complications and Survival to Total Hip Arthroplasty Following Femoral Head Core Decompression. JAAOS Global Research And Reviews 2024, 8: e24.00153. PMCID: PMC11578193, DOI: 10.5435/jaaosglobal-d-24-00153.Peer-Reviewed Original ResearchFemoral head osteonecrosisHip fractureInvasive proceduresCore decompressionHigh-volume surgeon groupImpact of surgeon volumeTotal hip arthroplastyKaplan-Meier survival analysisHigh-volume surgeonsMinimally invasive procedureSurgeon volume categoriesStatistically significant differenceAssess complicationsPerioperative complicationsPostoperative complicationsElixhauser Comorbidity IndexAdult patientsVolume surgeonsTreatment optionsAdverse eventsSurgeon volumeSurgeon groupComorbidity indexMultivariate analysisComplicationsExtracorporeal Shock Wave Therapy Shows Comparative Results With Other Modalities for The Management of Plantar Fasciitis: A Systematic Review and Meta-Analysis
Tung W, Daher M, Covarrubias O, Herber A, Gianakos A. Extracorporeal Shock Wave Therapy Shows Comparative Results With Other Modalities for The Management of Plantar Fasciitis: A Systematic Review and Meta-Analysis. Foot And Ankle Surgery 2024 PMID: 39572278, DOI: 10.1016/j.fas.2024.11.005.Peer-Reviewed Original ResearchEffect of extracorporeal shock wave therapyExtracorporeal shock wave therapyPlantar fasciitisRandomized controlled trialsShock wave therapyManagement of plantar fasciitisMeta-analysisPost intervention VAS scoreTreatment modalitiesWave therapyVAS pain scoresConservative treatment optionsCustom orthoticsHeel painPain scoresSystematic reviewVAS scoreControlled trialsTreatment optionsGoogle ScholarPlaceboFasciitisTherapyModalitiesScoresRadiation Therapy for the Treatment of Osteoarthritis
Yu J, Grew D, Spraker M, Beckta J, Shah C, Brower J. Radiation Therapy for the Treatment of Osteoarthritis. Practical Radiation Oncology 2024, 15: 19-24. PMID: 39503700, DOI: 10.1016/j.prro.2024.09.003.Peer-Reviewed Original ResearchConceptsRadiation therapyAssessment of treatment responseTreatment of osteoarthritisMedically refractory diseaseNonsteroidal anti-inflammatory drugsNoninvasive treatment optionCause of painCyclooxygenase-2 inhibitorsIntra-articular corticosteroid therapyAnti-inflammatory drugsCorticosteroid therapyRefractory diseaseTreatment responseTreatment optionsClinical evidenceOlder patientsTherapyCyclooxygenase-2PatientsTraditional treatmentPhysical therapyPainTreatmentOsteoarthritisTechnical considerationsOpen Reconstruction of Fibular Collateral Ligament Rupture Using a Partial-Thickness Biceps Femoris Tendon Autograft
Sabzevari S, Levitt S, Kahan J, Vasavada K, Fanelli G, LaPrade R, Medvecky M. Open Reconstruction of Fibular Collateral Ligament Rupture Using a Partial-Thickness Biceps Femoris Tendon Autograft. Video Journal Of Sports Medicine 2024, 4: 26350254241291595. DOI: 10.1177/26350254241291595.Peer-Reviewed Original ResearchFibular collateral ligament reconstructionFibular collateral ligamentBiceps femoris tendonMedial collateral ligament injuryPartial-thicknessUnderused treatment optionReturn to sportCost-effective surgeryWritten form of approvalFemoral tunnelCollateral ligament injuriesPredominant treatment approachCollateral ligament ruptureRange of motionStatement of releaseMultiligamentous injuriesClinical outcomesTreatment optionsMid-aspectOpen reconstructionAllograft tissueGraft harvestingTendon autograftFunctional recoveryHealing rateCan ChatGPT-4 Diagnose and Treat Like an Orthopaedic Surgeon? Testing Clinical Decision Making and Diagnostic Ability in Soft-Tissue Pathologies of the Foot and Ankle.
Hartman H, Essis M, Tung W, Oh I, Peden S, Gianakos A. Can ChatGPT-4 Diagnose and Treat Like an Orthopaedic Surgeon? Testing Clinical Decision Making and Diagnostic Ability in Soft-Tissue Pathologies of the Foot and Ankle. Journal Of The American Academy Of Orthopaedic Surgeons 2024 PMID: 39442011, DOI: 10.5435/jaaos-d-24-00595.Peer-Reviewed Original ResearchAverage sum scoreOrthopaedic surgeonsProfessional licensure examinationPatient education materialsDecision-making capacityClinical decision makingAnkle pathologyAnkle casesTreatment optionsAnkleEducational materialsSum scoreLicensure ExaminationLikert scaleLower scoresCriterion 5Higher scoresSubgroup analysisFootAlternative treatment optionCriterion 1Criterion 2ScoresSoft tissue pathologySurgeon evaluation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply